Tyzeka FDA Approval History
FDA Approved: Yes (Discontinued) (First approved October 25, 2006)
Brand name: Tyzeka
Generic name: telbivudine
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Hepatitis B
Marketing Status: Discontinued
Tyzeka (telbivudine) is a synthetic thymidine nucleoside analogue indicated for the treatment of chronic hepatitis B.
Development Timeline for Tyzeka
|Oct 25, 2006||Tyzeka Novartis - Treatment for Chronic Hepatitis B|
|Jan 3, 2006||Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the Treatment of Chronic Hepatitis B|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.